➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Harvard Business School
Merck
Express Scripts
AstraZeneca

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Patent: 10,106,621

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,106,621
Title:Immunotherapeutic molecules and uses
Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.
Inventor(s): Cobbold; Mark (Winchester, MA), Millar; David (Winchester, MA)
Assignee: The University of Birmingham (Birmingham, GB)
Application Number:15/708,419
Patent Claims:see list of patent claims

Details for Patent 10,106,621

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22 ⤷  Free Forever Trial The University of Birmingham (Birmingham, GB) 2032-02-28 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22 ⤷  Free Forever Trial The University of Birmingham (Birmingham, GB) 2032-02-28 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ⤷  Free Forever Trial The University of Birmingham (Birmingham, GB) 2032-02-28 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26 ⤷  Free Forever Trial The University of Birmingham (Birmingham, GB) 2032-02-28 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26 ⤷  Free Forever Trial The University of Birmingham (Birmingham, GB) 2032-02-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,106,621

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2013128194 ⤷  Free Forever Trial
United States of America 2015183875 ⤷  Free Forever Trial
United States of America 2016039942 ⤷  Free Forever Trial
United States of America 2018105599 ⤷  Free Forever Trial
United States of America 9650445 ⤷  Free Forever Trial
United States of America 9822180 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Harvard Business School
Dow
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.